Journal of Urologic Oncology

Editorial

November 30, 2023

Summarizing the Intentions and Outcomes of JUO 2023 Issue 3

Cheol Kwak

J Urol Oncol. 2023;21(3):181-182.

Invited Review

November 30, 2023

Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma

Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, et al.

J Urol Oncol. 2023;21(3):183-199.

The purpose of this review is to provide an up-to-date understanding of the literature describing the impact of body composition on renal cell carcinoma (RCC) prognosis and outcomes. Although obesity...

Topic Article

November 30, 2023

Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis

Jin Noh, Sang Hun Song, Gyoohwan Jung, et al.

J Urol Oncol. 2023;21(3):200-207.

Purpose: This study investigated the effects of preoperative renal artery embolization (PRAE) before radical nephrectomy (RN) for advanced nonmetastatic renal cell carcinoma (RCC) on perioperative and oncologic outcomes. Materials and Methods:...

Invited Review

November 30, 2023

The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects

Hyerim Ha, Joo Han Lim

J Urol Oncol. 2023;21(3):208-216.

Renal cell carcinoma (RCC) remains a significant challenge in oncology, prompting thorough investigations into adjuvant treatments aimed at enhancing both survival and quality of life for patients. In this review,...

Invited Review

November 30, 2023

Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type

Chan Woo Wee, Jaeho Cho

J Urol Oncol. 2023;21(3):217-227.

Renal cell carcinoma (RCC) has traditionally been considered one of the most radioresistant tumors based on in vitro and clinical studies that utilized a low biologically effective dose. However, recent...

Invited Review

November 30, 2023

Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023

Jiwoong Yu, Hyun Hwan Sung

J Urol Oncol. 2023;21(3):228-240.

Bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) poses a significant clinical challenge, prompting a need for effective treatment options. Although radical cystectomy is a standard approach, it is burdened by...

Topic Article

November 30, 2023

Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer

Chung Un Lee, Wan Song, Minyong Kang, et al.

J Urol Oncol. 2023;21(3):241-248.

Purpose: Radical cystectomy (RC) is recommended for patients with non–muscle-invasive bladder cancer (NMIBC) who are unresponsive to intravesical bacillus Calmette-Guérin (BCG) instillation. However, RC is a very risky treatment, and...

Original Article

November 30, 2023

Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy

Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al.

J Urol Oncol. 2023;21(3):249-256.

Purpose: The efficacy of standard chemotherapy or radical cystectomy in patients who have urothelial tumors with variant histology (VH) is very limited in terms of their prognosis. This study aimed...

Topic Article

November 30, 2023

Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Jaeyoung Cho, Jungyo Suh, Dalsan You, et al.

J Urol Oncol. 2023;21(3):257-263.

Purpose: This study aimed to identify predictive factors for the response to abiraterone in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Materials and Methods: This study analyzed the clinical characteristics...

Topic Article

November 30, 2023

Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy

Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, et al.

J Urol Oncol. 2023;21(3):264-270.

Purpose: In present, the use of androgen receptor targeting agents (ARTA) is one of the standard treatments for metastatic castration-resistant prostate cancer (mCRPC) without previous chemotherapy. However, some patients may...

Original Article

November 30, 2023

Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel

Tae Hwan Kim, Seol Ho Choo, Kang Hee Shim, et al.

J Urol Oncol. 2023;21(3):271-276.

Purpose: We propose a new potential marker of progression-free survival (PFS) called negative delta-prostate-specific antigen (PSA) time ratio (NDPSATR) and compare it with conventional PSA response, defined as PSA decline...

Erratum: Addition of the second author

November 30, 2023

Clinical Significance of Rab27a as a Urinary Biomarker in Patients With Bladder Cancer

Ja Yoon Ku, Md Nazmul Huda, Eu Chang Hwang, et al.

J Urol Oncol. 2023;21(3):277-277.

Summarizing the Intentions and Outcomes of JUO 2023 Issue 3 Cheol Kwak J Urol Oncol. 2023;21(3):181-182. Editorial Nov 30, 2023 Full text PubReader ePub PDF	Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, et al. J Urol Oncol. 2023;21(3):183-199. Cited By 1 Invited Review Nov 30, 2023 Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma Full text PubReader ePub PDF
Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis Jin Noh, Sang Hun Song, Gyoohwan Jung, et al. J Urol Oncol. 2023;21(3):200-207. Cited By 1 Topic Article Nov 30, 2023 Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma Full text PubReader ePub PDF	The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects Hyerim Ha, Joo Han Lim J Urol Oncol. 2023;21(3):208-216. Cited By 1 Invited Review Nov 30, 2023 Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma Full text PubReader ePub PDF
Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type Chan Woo Wee, Jaeho Cho J Urol Oncol. 2023;21(3):217-227. Cited By 1 Invited Review Nov 30, 2023 Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma Full text PubReader ePub PDF	Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023 Jiwoong Yu, Hyun Hwan Sung J Urol Oncol. 2023;21(3):228-240. Cited By 1 Invited Review Nov 30, 2023 Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Full text PubReader ePub PDF
Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer Chung Un Lee, Wan Song, Minyong Kang, et al. J Urol Oncol. 2023;21(3):241-248. Cited By 1 Topic Article Nov 30, 2023 Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Full text PubReader ePub PDF	Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al. J Urol Oncol. 2023;21(3):249-256. Cited By 1 Original Article Nov 30, 2023 Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Full text PubReader ePub PDF
Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer Jaeyoung Cho, Jungyo Suh, Dalsan You, et al. J Urol Oncol. 2023;21(3):257-263. Cited By 1 Topic Article Nov 30, 2023 Clinical Predictors of ARTA Response in Metastatic Prostate Cancer Full text PubReader ePub PDF	Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, et al. J Urol Oncol. 2023;21(3):264-270. Cited By 1 Topic Article Nov 30, 2023 Clinical Predictors of ARTA Response in Metastatic Prostate Cancer Full text PubReader ePub PDF
Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel Tae Hwan Kim, Seol Ho Choo, Kang Hee Shim, et al. J Urol Oncol. 2023;21(3):271-276. Cited By 1 Original Article Nov 30, 2023 Clinical Predictors of ARTA Response in Metastatic Prostate Cancer Full text PubReader ePub PDF	Clinical Significance of Rab27a as a Urinary Biomarker in Patients With Bladder Cancer Ja Yoon Ku, Md Nazmul Huda, Eu Chang Hwang, et al. J Urol Oncol. 2023;21(3):277-277. Corrects: J Urol Oncol 2022;20(1):52 Erratum: Addition of the second author Nov 30, 2023 Full text PubReader ePub PDF

4,313	Utility of Next-Generation Sequencing for Deciphering Intratumor Heterogeneity in Prostate Cancer
4,174	Understanding Cancer Pain and Controlling Pain: Focusing on Patients With Metastatic Urologic Cancer
4,010	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment
3,981	Expert Group Consensus Opinion on Prostate Cancer Diagnosis and Management in India: Part 2 of 2
3,941	Laparoscopic Radical Cystectomy With Intracorporeal Orthotopic Neobladder Reconstruction: An Initial Experience of Modified Studer Reconstruction Techniques

Cited By 2	Complex Epidemiology of Prostate Cancer in Asian Countries
Cited By 2	Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Cited By 2	Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use
Cited By 1	Understanding Cancer Pain and Controlling Pain: Focusing on Patients With Metastatic Urologic Cancer
Cited By 1	The Effects of Recombinant Bacillus Calmette-Guérin Resistant to Antimicrobial Peptides on Orthotopic Bladder Cancer Mouse Model